Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191]

Premal H Thaker¹, Debra L Richardson², Andrea R Hagemann³, Robert W Holloway⁴, Mark Reed⁵, Melanie K Bergman⁶, Bhavana Pothuri⁷, Stephen DePasquale⁸, Jennifer M Scalici⁹, Amy J Bregar¹⁰, Christopher J Darus¹¹, Karen Finkelstein¹², Charles A Leath 3rd¹³, Maria Bell¹⁴, David P Warshal¹⁵, Richy Agajanian¹⁶, Megan D Indermaur¹⁷, Alberto A Mendivil¹⁸, Diane M Provencher¹⁹, Lee-Jen Wei²⁰, Nicholas Borys²¹, Lauren Musso²², Stacy R Lindborg²³, Douglas V Faller²⁴, Khursheed Anwer²⁵, William H Bradley²⁶

Affiliations

¹ Washington University School of Medicine, St. Louis, MO, USA. Electronic address: thakerp@wustl.edu.
² Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA. Electronic address: Debra-Richardson@ouhsc.edu.
³ Washington University School of Medicine, St. Louis, MO, USA. Electronic address: hagemanna@wustl.edu.
⁴ AdventHealth Cancer Institute, Orlando, FL, USA.
⁵ West Cancer Center & Research Institute, Germantown, TN, USA. Electronic address: mreed@westclinic.com.
⁶ Providence Sacred Heart, Spokane, WA, USA. Electronic address: Melanie.Bergman@providence.org.
⁷ Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA. Electronic address: bhavana.pothuri@nyulangone.org.
⁸ Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA.
⁹ University of South Alabama, Birmingham, AL, USA. Electronic address: jennifer.m.scalici@emory.edu.
¹⁰ Massachusetts General Hospital, Boston, MA, USA. Electronic address: ABREGAR@mgh.harvard.edu.
¹¹ Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. Electronic address: christopher.darus@providence.org.
¹² OPTIMUM, Albuquerque, NM, USA. Electronic address: karen@swgynonc.com.
¹³ University of Alabama Birmingham, Birmingham, AL, USA. Electronic address: cleath@uabmc.edu.
¹⁴ Sanford Health, Sioux Falls, SD, USA. Electronic address: Maria.Bell@SanfordHealth.org.
¹⁵ Cooper Health MD Anderson, Camden, NJ, USA. Electronic address: Warshal-David@CooperHealth.edu.
¹⁶ The Oncology Institute of Hope & Innovation, Long Beach, CA, USA. Electronic address: AgajanianMD@theoncologyinstitute.com.
¹⁷ Women's Care Florida, St. Petersberg, FL, USA. Electronic address: mindermaur@WomensCareFL.com.
¹⁸ Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. Electronic address: alberto.mendivil@hoag.org.
¹⁹ Universite de Montreal, Montreal, Quebec, Canada. Electronic address: diane.provencher.chum@ssss.gouv.qc.ca.
²⁰ Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: wei@hsph.harvard.edu.
²¹ Imunon, Lawrenceville, NJ, USA.
²² Imunon, Lawrenceville, NJ, USA. Electronic address: LMusso@imunon.com.
²³ Imunon, Lawrenceville, NJ, USA. Electronic address: slindborg@imunon.com.
²⁴ Imunon, Lawrenceville, NJ, USA. Electronic address: dfaller@imunon.com.
²⁵ Imunon, Lawrenceville, NJ, USA. Electronic address: KAnwer@imunon.com.
²⁶ Froedtert Hospital & Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: wbradley@mcw.edu.

PMID: 41202407
DOI: 10.1016/j.ygyno.2025.10.031

Published Erratum

Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191]

Premal H Thaker et al. Gynecol Oncol. 2025.

. 2025 Nov 6:203:182-183.

doi: 10.1016/j.ygyno.2025.10.031. Online ahead of print.

Authors

Affiliations

¹ Washington University School of Medicine, St. Louis, MO, USA. Electronic address: thakerp@wustl.edu.
² Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA. Electronic address: Debra-Richardson@ouhsc.edu.
³ Washington University School of Medicine, St. Louis, MO, USA. Electronic address: hagemanna@wustl.edu.
⁴ AdventHealth Cancer Institute, Orlando, FL, USA.
⁵ West Cancer Center & Research Institute, Germantown, TN, USA. Electronic address: mreed@westclinic.com.
⁶ Providence Sacred Heart, Spokane, WA, USA. Electronic address: Melanie.Bergman@providence.org.
⁷ Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA. Electronic address: bhavana.pothuri@nyulangone.org.
⁸ Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA.
⁹ University of South Alabama, Birmingham, AL, USA. Electronic address: jennifer.m.scalici@emory.edu.
¹⁰ Massachusetts General Hospital, Boston, MA, USA. Electronic address: ABREGAR@mgh.harvard.edu.
¹¹ Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. Electronic address: christopher.darus@providence.org.
¹² OPTIMUM, Albuquerque, NM, USA. Electronic address: karen@swgynonc.com.
¹³ University of Alabama Birmingham, Birmingham, AL, USA. Electronic address: cleath@uabmc.edu.
¹⁴ Sanford Health, Sioux Falls, SD, USA. Electronic address: Maria.Bell@SanfordHealth.org.
¹⁵ Cooper Health MD Anderson, Camden, NJ, USA. Electronic address: Warshal-David@CooperHealth.edu.
¹⁶ The Oncology Institute of Hope & Innovation, Long Beach, CA, USA. Electronic address: AgajanianMD@theoncologyinstitute.com.
¹⁷ Women's Care Florida, St. Petersberg, FL, USA. Electronic address: mindermaur@WomensCareFL.com.
¹⁸ Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. Electronic address: alberto.mendivil@hoag.org.
¹⁹ Universite de Montreal, Montreal, Quebec, Canada. Electronic address: diane.provencher.chum@ssss.gouv.qc.ca.
²⁰ Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: wei@hsph.harvard.edu.
²¹ Imunon, Lawrenceville, NJ, USA.
²² Imunon, Lawrenceville, NJ, USA. Electronic address: LMusso@imunon.com.
²³ Imunon, Lawrenceville, NJ, USA. Electronic address: slindborg@imunon.com.
²⁴ Imunon, Lawrenceville, NJ, USA. Electronic address: dfaller@imunon.com.
²⁵ Imunon, Lawrenceville, NJ, USA. Electronic address: KAnwer@imunon.com.
²⁶ Froedtert Hospital & Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: wbradley@mcw.edu.

PMID: 41202407
DOI: 10.1016/j.ygyno.2025.10.031

No abstract available

PubMed Disclaimer

Erratum for

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Thaker PH, Richardson DL, Hagemann AR, Holloway RW, Reed M, Bergman MK, Pothuri B, DePasquale S, Scalici JM, Bregar AJ, Darus CJ, Finkelstein K, Leath CA 3rd, Bell M, Warshal DP, Agajanian R, Indermaur MD, Mendivil AA, Provencher DM, Wei LJ, Borys N, Musso L, Lindborg SR, Faller DV, Anwer K, Bradley WH. Thaker PH, et al. Gynecol Oncol. 2025 Jun;197:182-191. doi: 10.1016/j.ygyno.2025.04.578. Epub 2025 Jun 3. Gynecol Oncol. 2025. PMID: 40461366 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191]

Affiliations

Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 197 182-191]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous